Biosimilars

Cipla acquires mAb manufacturer Mabpharm

Cipla acquires mAb manufacturer Mabpharm

By Zachary Brennan

Indian biopharma Cipla is pushing further into the realm of monoclonal antibody manufacturing with its purchase of India-based Mabpharm.

The cost savings of biosimilars is seen as a reason to allow similar INNs for biosimilars and biologics.

GPhA, retirees and pharmacies call for same INNs for biosimilars

By Zachary Brennan

The fight over how biosimilars should be named in the US just got more tense as a group of pharmacists, pension systems and the Generic Pharmaceutical Association are calling for a system similar to what’s used in the EU, with the same INNs (international...

EU green lights first insulin biosimilar from Lilly, BI

EU green lights first insulin biosimilar from Lilly, BI

By Zachary Brennan

The EU’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended granting a marketing authorisation to Boehringer Ingelheim and Eli Lilly’s biosimilar insulin treatment for Type 1 and Type 2 diabetes patients.

Follow us

Products

View more

Webinars